vs
ACACIA RESEARCH CORP（ACTG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ACACIA RESEARCH CORP的季度营收约是REGENXBIO Inc.的1.7倍（$50.1M vs $30.3M），ACACIA RESEARCH CORP净利率更高（6.8% vs -221.3%，领先228.2%），REGENXBIO Inc.同比增速更快（43.0% vs 2.6%），过去两年ACACIA RESEARCH CORP的营收复合增速更高（43.6% vs 39.4%）
槐亚研究公司是一家总部位于纽约市的美国上市企业，在科技、能源以及工业制造领域开展业务收购与运营工作。该公司与控股股东斯塔博德价值投资合伙企业保持战略伙伴关系，这家企业在业内常被归类为专利流氓。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ACTG vs RGNX — 直观对比
营收规模更大
ACTG
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出40.4%
2.6%
净利率更高
ACTG
高出228.2%
-221.3%
两年增速更快
ACTG
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.1M | $30.3M |
| 净利润 | $3.4M | $-67.1M |
| 毛利率 | 12.8% | — |
| 营业利润率 | -26.1% | -190.0% |
| 净利率 | 6.8% | -221.3% |
| 营收同比 | 2.6% | 43.0% |
| 净利润同比 | 125.5% | -31.2% |
| 每股收益（稀释后） | $0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACTGRGNX
| Q4 25 | $50.1M | $30.3M | ||
| Q3 25 | $59.4M | $29.7M | ||
| Q2 25 | $51.2M | $21.4M | ||
| Q1 25 | $124.4M | $89.0M | ||
| Q4 24 | $48.8M | $21.2M | ||
| Q3 24 | $23.3M | $24.2M | ||
| Q2 24 | $25.8M | $22.3M | ||
| Q1 24 | $24.3M | $15.6M |
净利润ACTGRGNX
| Q4 25 | $3.4M | $-67.1M | ||
| Q3 25 | $-2.7M | $-61.9M | ||
| Q2 25 | $-3.3M | $-70.9M | ||
| Q1 25 | $24.3M | $6.1M | ||
| Q4 24 | $-13.4M | $-51.2M | ||
| Q3 24 | $-14.0M | $-59.6M | ||
| Q2 24 | $-8.4M | $-53.0M | ||
| Q1 24 | $-186.0K | $-63.3M |
毛利率ACTGRGNX
| Q4 25 | 12.8% | — | ||
| Q3 25 | 21.2% | — | ||
| Q2 25 | 12.8% | — | ||
| Q1 25 | 47.4% | — | ||
| Q4 24 | 17.6% | 70.2% | ||
| Q3 24 | 10.1% | 48.8% | ||
| Q2 24 | 26.2% | 52.5% | ||
| Q1 24 | 49.2% | 72.6% |
营业利润率ACTGRGNX
| Q4 25 | -26.1% | -190.0% | ||
| Q3 25 | -10.8% | -176.3% | ||
| Q2 25 | -24.2% | -296.3% | ||
| Q1 25 | 30.8% | 13.6% | ||
| Q4 24 | -32.4% | -242.1% | ||
| Q3 24 | -44.1% | -256.6% | ||
| Q2 24 | -18.4% | -251.3% | ||
| Q1 24 | -8.6% | -408.8% |
净利率ACTGRGNX
| Q4 25 | 6.8% | -221.3% | ||
| Q3 25 | -4.6% | -208.3% | ||
| Q2 25 | -6.4% | -331.8% | ||
| Q1 25 | 19.5% | 6.8% | ||
| Q4 24 | -27.5% | -241.3% | ||
| Q3 24 | -60.0% | -246.3% | ||
| Q2 24 | -32.7% | -237.7% | ||
| Q1 24 | -0.8% | -405.4% |
每股收益（稀释后）ACTGRGNX
| Q4 25 | $0.03 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.03 | $-1.38 | ||
| Q1 25 | $0.25 | $0.12 | ||
| Q4 24 | $-0.14 | $-0.99 | ||
| Q3 24 | $-0.14 | $-1.17 | ||
| Q2 24 | $-0.08 | $-1.05 | ||
| Q1 24 | $0.00 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.7M | $230.1M |
| 总债务越低越好 | $91.9M | — |
| 股东权益账面价值 | $543.5M | $102.7M |
| 总资产 | $771.0M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资ACTGRGNX
| Q4 25 | $306.7M | $230.1M | ||
| Q3 25 | $301.8M | $274.2M | ||
| Q2 25 | $316.7M | $323.3M | ||
| Q1 25 | $272.0M | $267.9M | ||
| Q4 24 | $273.9M | $234.7M | ||
| Q3 24 | $410.9M | $255.5M | ||
| Q2 24 | $441.9M | $290.4M | ||
| Q1 24 | $498.4M | $338.7M |
总债务ACTGRGNX
| Q4 25 | $91.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACTGRGNX
| Q4 25 | $543.5M | $102.7M | ||
| Q3 25 | $537.6M | $161.5M | ||
| Q2 25 | $538.6M | $213.7M | ||
| Q1 25 | $540.2M | $274.2M | ||
| Q4 24 | $514.8M | $259.7M | ||
| Q3 24 | $540.2M | $301.4M | ||
| Q2 24 | $560.7M | $348.3M | ||
| Q1 24 | $568.3M | $390.7M |
总资产ACTGRGNX
| Q4 25 | $771.0M | $453.0M | ||
| Q3 25 | $768.9M | $525.2M | ||
| Q2 25 | $775.5M | $581.0M | ||
| Q1 25 | $801.6M | $490.9M | ||
| Q4 24 | $756.4M | $466.0M | ||
| Q3 24 | $707.6M | $519.1M | ||
| Q2 24 | $753.6M | $569.4M | ||
| Q1 24 | $631.7M | $629.2M |
负债/权益比ACTGRGNX
| Q4 25 | 0.17× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 22.01× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ACTGRGNX
| Q4 25 | $75.2M | $-52.3M | ||
| Q3 25 | $9.5M | $-56.0M | ||
| Q2 25 | $50.1M | $-49.3M | ||
| Q1 25 | $2.4M | $33.6M | ||
| Q4 24 | $50.1M | $-31.6M | ||
| Q3 24 | $-593.0K | $-40.5M | ||
| Q2 24 | $16.1M | $-45.5M | ||
| Q1 24 | $54.8M | $-55.5M |
自由现金流ACTGRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $335.0K | $32.6M | ||
| Q4 24 | $-98.5M | $-32.7M | ||
| Q3 24 | $-2.8M | $-40.9M | ||
| Q2 24 | $-126.7M | $-46.0M | ||
| Q1 24 | $54.6M | $-56.0M |
自由现金流率ACTGRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | 0.3% | 36.6% | ||
| Q4 24 | -201.8% | -154.2% | ||
| Q3 24 | -12.1% | -168.9% | ||
| Q2 24 | -490.5% | -206.2% | ||
| Q1 24 | 224.4% | -358.5% |
资本支出强度ACTGRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | 1.7% | 1.2% | ||
| Q4 24 | 304.4% | 5.1% | ||
| Q3 24 | 9.6% | 1.3% | ||
| Q2 24 | 553.0% | 2.1% | ||
| Q1 24 | 1.1% | 3.6% |
现金转化率ACTGRGNX
| Q4 25 | 22.01× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.10× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACTG
| Energy Operations | $16.0M | 32% |
| Transportation Safety | $10.4M | 21% |
| Office Storage And Display Solutions | $8.4M | 17% |
| Printers Consumables And Parts | $6.5M | 13% |
| Natural Gas Reserves | $5.1M | 10% |
| Natural Gas Liquids Reserves | $3.3M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
